MNG880
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.451
- E2F_TARGETS+0.437
- G2M_CHECKPOINT+0.364
- DNA_REPAIR+0.332
- CHOLESTEROL_HOMEOSTASIS+0.274
- OXIDATIVE_PHOSPHORYLATION+0.274
- PROTEIN_SECRETION+0.247
- HEME_METABOLISM+0.241
- MTORC1_SIGNALING+0.198
- PEROXISOME+0.172
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.544
- APICAL_SURFACE-0.533
- HYPOXIA-0.336
- KRAS_SIGNALING_UP-0.297
- INFLAMMATORY_RESPONSE-0.290
- IL6_JAK_STAT3_SIGNALING-0.285
- MYOGENESIS-0.284
- HEDGEHOG_SIGNALING-0.269
- IL2_STAT5_SIGNALING-0.246
- ANGIOGENESIS-0.241
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3IS-01A-21R-A21D-07 | — | — | 0.865 |
| 2 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.865 |
| 3 | MNG832 | — | — | 0.861 |
| 4 | BS_QXKRN6CR | EPN | Supratentorial EPN | 0.853 |
| 5 | BS_QXKRN6CR | Supratentorial Ependymoma | — | 0.850 |
| 6 | BS_7G42J2SK | Supratentorial Ependymoma | — | 0.845 |
| 7 | BS_H4NXBD2D | Supratentorial Ependymoma | — | 0.843 |
| 8 | BS_EK5PCKY0 | Supratentorial Ependymoma | — | 0.840 |
| 9 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.836 |
| 10 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.451 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.437 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.364 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.332 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.274 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.274 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.247 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.241 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.198 | Inavolisib | — uncovered |
| PEROXISOME | 0.172 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.169 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.153 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.145 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.122 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.104 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.093 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.083 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.078 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.073 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.049 | Idelalisib | — uncovered |